Aciont
Envisioning the Future of Ocular Therapeutics
About Us | Unmet Needs | Technologies | Product Pipeline | Media & Investors
News

News

This menu lists current news relating to corporate activities and resources or internet links relating to our industry.

Phase 1/2 Uveitis Clinical Trial Evaluating DSP-Visulex-TM Now Open for Enrollment - 12/02/2014
Salt Lake City, UT- December 2, 2014 – Aciont Inc., a specialty biopharmaceutical company endeavoring to become a leader in non-invasive drug delivery treatments for sight threatening diseases, announced that its DSPV-201 clinical study is open for enrollment to patients at study sites located in the United States. Currently, both the Ocular Immunology and Uveitis Foundation at Massachusetts Eye Research and Surgery Institution (MERSI) and the Retina and Uveitis Consultants of Texas (RUCT) are open for enrollment.
 
The NEI Awards $2.03 Million Commercialization SBIR Grant to Aciont - 05/09/2013
Salt Lake City, UT – May 9, 2013. The National Eye Institute (NEI), a division of the National Institutes of Health (NIH), awarded a $2.03 million phase IIB grant to Aciont Inc. to fund the clinical development of a non-invasive, passive diffusion-based treatment for uveitis (referred to as DSP-Visulex-TM). The NEI special emphasis peer review panel that reviewed Aciont’s proposal stated, “Overall, this is a novel, exciting approach that has potential to make a broad impact in the clinical ophthalmology field and thus is recommended with a high level of enthusiasm.”
 
Aciont® to Present at ARVO 2013 Annual Meeting - 04/15/2013
Aciont Inc. announced today that Dr. Sarah A. Molokhia and Dr. Kongnara Papangkorn will present recent findings on two Visulex-TM technologies
 
Aciont® To Present on VisulexTM Technologies at the 4th Ocular & Drug Discovery Conference - 01/10/2012
Kongnara Papankorn and Sarah Molokhia will present on behalf of Aciont Inc at the Global Technology Community’s 4th Ocular & Drug Discovery Conference, February 27-28, 2012, in Las Vegas, NV
 
Aciont® CEO to Present at IN3 West Medical Device Conference - 02/08/2011
John Higuchi will present on behalf of Aciont Inc at the IN3 West Medical Device Conference.
 
Aciont® Awarded Two Qualifying Therapeutic Discovery Project Grants Totaling $489K - 11/04/2010
Aciont Inc. announced today that it has been awarded $488,958 to support two projects under the U.S. Government’s Qualifying Therapeutic Discovery Project (QTDP) program.
 
University of Michigan Science Symposium Honoring Professor William I. Higuchi - 09/23/2010

 
The NIH Awards Aciont® a Small Business Catalyst Award Grant Accelerating Innovative Research - 07/07/2010
Aciont is awarded a phase I SBIR $214K grant for the project titled "Novel Method for the Ocular Iontophoretic Delivery of Avastin® and Lucentis®"
 
Aciont® To Present at ARVO 2010 Annual Meeting - 04/09/2010

 
NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont® - 12/10/2009
The National Eye Institute (NEI) awarded a $2.18 million grant to Aciont Inc. to help fund its development of a non-invasive, passive diffusion-based treatment for severe, non-infectious uveitis.
 
Aciont ARVO 2009 Presentations Article - 05/04/2009

 
Tribute to William I. Higuchi in Journal of Pharmaceutical Sciences - 01/15/2008
Dr. Higuchi's contributions have significantly elevated the field of pharmaceutics. He has an impressive body of scientific work and a continuing legacy of his accomplishments.
 
Aciont's Research Discussed in Two Recent Ophthalmic Publications - 11/21/2008
Aciont's research is published in Investigative Ophthalmology & Visual Science journal and Journal of Ocular Pharmacology and Therapeutics.
 
NEI Awards Ocular Iontophoresis Research Grant to Aciont® Collaborators - 01/18/2007
Understanding of ocular pharmacokinetics and transport barriers of the eye would be a major step toward achieving a non-invasive drug delivery system to treat posterior segment of eye diseases.
 
Aciont® Featured in Retina Today Article - 03/01/2007
Dr. Karl G. Csaky's article features new and exciting technologies in transscleral drug delivery.
 
Aciont Announces SBIR Funding to Support the Development of its Back-of-the-Eye Therapy Technology - November 2004 - 11/09/2004

 
Aciont's Visulex Technology Highlighted in Leading Drug Delivey Trade Magazine - 04/15/2004
Advancing iontophoresis for effective noninvasive back-of-the-eye therapeutics.
 
Aciont® Featured in Digital IQ Article - 06/04/2003

 
Aciont® Inc Awarded NIH Grant - 04/25/2002
Awarded a Phase-I Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH) for $100,000 payment based on the competitive merit of Aciont's proposal and technology.